NVCR - NovoCure Limited
After hours:
| Previous close | 74.90 |
| Open | 76.00 |
| Bid | 76.35 x 900 |
| Ask | 79.38 x 800 |
| Day's range | 73.24 - 79.62 |
| 52-week range | 56.06 - 120.03 |
| Volume | |
| Avg. volume | 707,406 |
| Market cap | 8.446B |
| Beta (5Y monthly) | 0.81 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.40 |
| Earnings date | 26 July 2023 - 31 July 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 97.71 |
Business WireNovocure Pledges $3 Million to Conquer Cancer®, the ASCO Foundation, to Support Cancer Research and Education
ROOT, Switzerland, June 01, 2023--Novocure (NASDAQ: NVCR) today announced that it will donate $3 million to Conquer Cancer®, the ASCO Foundation, to advance cancer research and education.
Motley Fool3 No-Brainer Stocks to Buy for Under $100 Right Now
Here's why they chose CRISPR Therapeutics (NASDAQ: CRSP), Novocure (NASDAQ: NVCR), and Pfizer (NYSE: PFE). David Jagielski (CRISPR Therapeutics): Shares of CRISPR Therapeutics are trading below $70, but it may not be long before they take off. The company has a promising gene-editing therapy in exa-cel for rare blood disorders beta-thalassemia and sickle cell disease that it has been working on with Vertex Pharmaceuticals.
Simply Wall St.NovoCure Limited's (NASDAQ:NVCR) Business Is Trailing The Industry But Its Shares Aren't
With a price-to-sales (or "P/S") ratio of 13.6x NovoCure Limited ( NASDAQ:NVCR ) may be sending very bearish signals at...
Motley FoolShould You Buy Novocure Stock Right Now?
Should you buy Novocure stock right now? When a stock falls as much as Novocure has over the last couple of years or so, there's always an underlying reason. The main factor behind Novocure's decline is that its business isn't performing all that well.
Motley FoolNovoCure (NVCR) Q1 2023 Earnings Call Transcript
Image source: The Motley Fool. NovoCure (NASDAQ: NVCR)Q1 2023 Earnings CallMay 04, 2023, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood day, and thank you for standing by.
ZacksNovoCure (NVCR) Reports Q1 Loss, Lags Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of -38.89% and 4.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Business WireNovocure Reports First Quarter 2023 Financial Results
ROOT, Switzerland, May 04, 2023--Novocure Reports First Quarter 2023 Financial Results
Business WireNovocure Announces Presentation of Results of the LUNAR Phase 3 Clinical Trial in Non-Small Cell Lung Cancer at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
ROOT, Switzerland, April 26, 2023--Novocure (NASDAQ: NVCR) today announced the results of the LUNAR phase 3 clinical trial in metastatic, non-small cell lung cancer (NSCLC) will be presented for the first time at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, to be held from June 2 to June 6.
Business WireNovocure Announces 27 Presentations, Including Real-World Evidence and Preclinical Research, at American Association for Cancer Research (AACR) Annual Meeting 2023
ROOT, Switzerland, April 14, 2023--Novocure (NASDAQ: NVCR) today announced 27 presentations on Tumor Treating Fields (TTFields) will be delivered at the American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14 to 19 in Orlando, Florida.
- Simply Wall St.
NovoCure (NASDAQ:NVCR) shareholder returns have been solid, earning 194% in 5 years
The last three months have been tough on NovoCure Limited ( NASDAQ:NVCR ) shareholders, who have seen the share price...
Business WireNovocure to Report First Quarter 2023 Financial Results
ROOT, Switzerland, April 03, 2023--Novocure announced today that it will report financial results for the first quarter 2023 on May 4, 2023, before the U.S. financial markets open.
Business WireKristin Stafford Joins Novocure Board of Directors
ROOT, Switzerland, March 29, 2023--Novocure (NASDAQ: NVCR) today announced that Kristin Stafford has been elected to Novocure’s Board of Directors.
- Simply Wall St.
Institutional investors may adopt severe steps after NovoCure Limited's (NASDAQ:NVCR) latest 7.3% drop adds to a year losses
Key Insights Given the large stake in the stock by institutions, NovoCure's stock price might be vulnerable to their...
Business WireNovocure Announces 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
ROOT, Switzerland, March 16, 2023--Novocure today announced the 5th Annual AACR-Novocure Grants for Tumor Treating Fields Research Program.
Motley Fool2 Best Defensive Stocks to Buy in March
Keeping with this theme, Federal Reserve Chair Jerome Powell said Tuesday that the bank is considering raising interest rates faster and farther than previously anticipated in order to tamp down inflation. Defensive stocks could be a good way to protect your portfolio from downside risk. Which defensive stocks are top buys right now?
Business WireNovocure Announces Reimbursement of Optune® for the Treatment of Newly Diagnosed Glioblastoma in France
ROOT, Switzerland, March 01, 2023--Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly diagnosed glioblastoma (GBM) in France. The order registering Optune on the List of Reimbursable Products and Services (LPPR) provided for in Article L165-1 of the Social Security Code was published in the Official Journal on February 28, 2023 and will become effective March 15, 2023.
Business WireNovocure Announces Last Patient Enrolled in Pivotal METIS Study of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer
ROOT, Switzerland, March 01, 2023--Novocure announced that the final patient has enrolled in the pivotal METIS study.
- Simply Wall St.
NovoCure Full Year 2022 Earnings: US$0.88 loss per share (vs US$0.56 loss in FY 2021)
NovoCure ( NASDAQ:NVCR ) Full Year 2022 Results Key Financial Results Revenue: US$537.8m (flat on FY 2021). Net loss...
Motley FoolWhy NovoCure Stock Is Falling Today
Shares of the novel oncology company NovoCure (NASDAQ: NVCR) are trading lower today following the company's 2022 fourth-quarter and full-year results release this morning. Although the company's financial results were essentially in line with Wall Street's consensus estimates for the three-month period, investors were clearly looking for a stronger quarter from the cancer company. Perhaps the most concerning issue is that NovoCure's net revenue fell by 4% in Q4 to $128.4 million, relative to the same period a year ago.
- Motley Fool
NovoCure (NVCR) Q4 2022 Earnings Call Transcript
Image source: The Motley Fool. NovoCure (NASDAQ: NVCR)Q4 2022 Earnings CallFeb 23, 2023, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Ingrid Goldberg Good morning, everyone, and thank you for joining us to review NovoCure's fourth-quarter and full-year 2022 performance.
ZacksNovoCure (NVCR) Reports Q4 Loss, Misses Revenue Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of -12.50% and 0.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business WireAllyson J. Ocean, M.D., Joins Novocure Board of Directors
ROOT, Switzerland, February 23, 2023--Allyson J. Ocean, M.D., has been elected to Novocure’s Board of Directors. Dr. Ocean brings decades of experience in oncology to Novocure.
Business WireNovocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
ROOT, Switzerland, February 23, 2023--Novocure Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
ZacksAnalysts Estimate NovoCure (NVCR) to Report a Decline in Earnings: What to Look Out for
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Motley FoolWhy Novocure Stock Was so Healthy Today
In the biotech world, investors often heave a sigh of relief when an important clinical goal is met. Novocure announced that it has completed enrollment in its upcoming Panova-3 study of its Tumor Treating Fields product (TTFields). The clinical trial will gauge the efficacy of TTFields when administered in combination with chemotherapy treatments nabpaclitaxel and gemcitabine to fight locally advanced pancreatic cancer.
